70886-35-0

Basic information

• Product Name: 2-HYDROXY-5-NITROPHENYLFORMAMIDE
• Synonyms: 2-HYDROXY-5-NITROPHENYLFORMAMIDE
• CAS NO: 70886-35-0
• Molecular Formula: C₇H₆N₂O₄
• Molecular Weight: 182.13
• Mol File: 70886-35-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 453.4°Cat760mmHg
• Flash Point: 228°C
• Appearance: /
• Density: 1.563g/cm³
• Vapor Pressure: 7.72E-09mmHg at 25°C
• Refractive Index: 1.689
• CAS DataBase Reference: 2-HYDROXY-5-NITROPHENYLFORMAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-HYDROXY-5-NITROPHENYLFORMAMIDE(70886-35-0)
• EPA Substance Registry System: 2-HYDROXY-5-NITROPHENYLFORMAMIDE(70886-35-0)

Safety Data

• Hazardous Substances Data: 70886-35-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H6N2O4/c10-4-8-6-3-5(9(12)13)1-2-7(6)11/h1-4,11H,(H,8,10)

Upstream product

• 70886-33-8 5-nitro-benzooxazole 
• 64-18-6 formic acid 
• 99-57-0 2-hydroxy-5-nitroaniline 
• 615-18-9 2-chloro-1,3-benzoxazole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 70886-33-8 5-nitro-benzooxazole 
• 500311-95-5 N-(2-benzyloxy-5-nitrophenyl)-formamide 
• 191352-28-0 tert-butyl (2-hydroxy-5-nitrophenyl)(methyl)carbamate 
• 191352-29-1 (2S,3R,4S,5S,6S)-2-(2-((tert-butoxycarbonyl)(methyl)amino)-4-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 191352-30-4 (2S,3S,4S,5R,6S)-2-(methoxycarbonyl)-6-(2-(methylamino)-4-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 14703-72-1 2-(methylamino)-4-nitrophenol 

Relevant articles and documents

Heterocyclic Derivatives of 2-Amino-4-nitrophenol

A new pathway for the synthesis of cyclic derivatives of 2-amino-4-nitrophenol by application of dibromoalkanes is described. This general method was used for the preparation of several heterocycles (partially saturated 1,4-benzoxazines, 1,5-benzoxazepine

GLUCURONIDE PRODRUGS OF TOFACITINIB

The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I): (Formula (I)) where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

ORGANIC COMPOUNDS

Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer (such as prostate or breast cancer), osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.